Immunotherapeutic strategies have shown promise for the treatment of canine osteosarcoma (cOSA). Very little is known about the immune microenvironment within cOSA, however, limiting our ability to identify potential immune targets and biomarkers of therapeutic response. We therefore prospectively assessed the disease-free interval (DFI) and overall survival time (ST) of 30 dogs with cOSA treated with amputation and six doses of adjuvant carboplatin. We then quantified lymphocytic (CD3+, FOXP3+) and macrophage (CD204+) infiltrates within the primary tumours of this cohort using immunohistochemistry, and evaluated their association with outcome. Overall, the median DFI and ST were 392 and 455 days, respectively. The median number of CD3+ and FOXP3+ infiltrates were 45.8 cells/mm 2 (4.6-607.6 cells/mm (1.3%-23.3%), and dogs with tumours containing greater than 4.7% CD204+ macrophages experienced a significantly longer DFI (P = 0.016). Interestingly, a significantly lower percentage of CD204+ macrophages was detected in cOSA arising from the proximal humerus compared to other appendicular bone locations (P = 0.016). Lymphocytic infiltrates did not appear to correlate with outcome in cOSA. Overall, our findings suggest that macrophages may play a role in inhibiting cOSA progression, as has been suggested in human osteosarcoma.
Immunotherapeutic strategies have shown promise for the treatment of canine osteosarcoma (cOSA). Very little is known about the immune microenvironment within cOSA, however, limiting our ability to identify potential immune targets and biomarkers of therapeutic response. We therefore prospectively assessed the disease-free interval (DFI) and overall survival time (ST) of 30 dogs with cOSA treated with amputation and six doses of adjuvant carboplatin. We then quantified lymphocytic (CD3+, FOXP3+) and macrophage (CD204+) infiltrates within the primary tumours of this cohort using immunohistochemistry, and evaluated their association with outcome. Overall, the median DFI and ST were 392 and 455 days, respectively. The median number of CD3+ and FOXP3+ infiltrates were 45. (1.3%-23.3%), and dogs with tumours containing greater than 4.7% CD204+ macrophages experienced a significantly longer DFI (P = 0.016). Interestingly, a significantly lower percentage of CD204+ macrophages was detected in cOSA arising from the proximal humerus compared to other appendicular bone locations (P = 0.016). Lymphocytic infiltrates did not appear to correlate with outcome in cOSA. Overall, our findings suggest that macrophages may play a role in inhibiting cOSA progression, as has been suggested in human osteosarcoma.
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| INTRODUCTION
Canine osteosarcoma (OSA; cOSA) is a highly metastatic cancer with stagnant survival rates over the last 30 years. [1] [2] [3] Broadly, the best patient outcomes have been reported in dogs receiving amputation followed by platinum chemotherapy, with or without the addition of doxorubicin; however, the optimal chemotherapeutic protocol has not been precisely determined. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Unfortunately, 2-year survival rates remain around 20% and the majority of dogs still die from pulmonary metastases, warranting investigation into alternate strategies such as immunotherapy to improve survival. [1] [2] [3] [4] [5] [6] [7] [8] In an attempt to improve upon survival estimates for dogs with cOSA receiving standard cytotoxic chemotherapy regimens, several reports have described the addition of immune-targeting therapeutics.
First, the finding of limb-sparing associated wound infections as being a positive prognostic factor suggested innate immune responses may be important in delaying or preventing metastatic disease. 17, 18 Indeed, this observation was mechanistically supported by a subsequent study
showing the presence of macrophages and natural killer cells were essential for mediating the effect of wound infection on decreasing pulmonary metastases in a mouse model of OSA. 19 Furthermore, early studies recognized improved survival in dogs with cOSA treated with amputation followed by liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) alone compared to empty liposomes, or in a schedule-dependent combination with cisplatin compared to cisplatin alone. 20, 21 Interestingly, the anticancer activity of L-MTP-PE is also thought to be predominantly because of its ability to promote tumoricidal activity of monocytes and macrophages. 22 
| Tissue collection and processing
Archived formalin-fixed paraffin-embedded (FFPE) blocks of tissue collected from primary tumours immediately after amputation were retrieved and cut into 5 μm sections. Decalcified blocks were recorded. At least one slide from each tumour was stained with haematoxylin and eosin (H&E) and the remainder were adhered to charged slides in preparation for immunohistochemistry (IHC).
| IHC processing
Slides underwent standard methods of deparaffinization and rehydra- 
| IHC quantification
Three cellular ×100 fields on H&E stained slides from each tumour were selected to mimic previous studies in hOSA where three cellular 1 to 2 mm diameter areas within each block were chosen to create tissue microarrays. 27, 29, 49, 50 The scale was set using an image of a haemocytometer and Image J 1.51s (National Institutes of Health, Bethesda, MD), and determined to be 2041.8 pixels/mm at ×100 magnification. The area of each ×100 magnification image equalled
. These areas were marked and transposed onto IHC stained slides from each tumour so that similar areas of tissue were evaluated on subsequent slides for each marker evaluated. A Leica DM2000 was used to image each ×100 field, and images were digitalized using the attached Jenoptik ProgRes C5 camera.
To quantify CD3 and FOXP3 cellular infiltrates, Image J was used to measure the cellular area of each ×100 image, and to count the number of positive cells within that area. The area in pixels was then converted to mm 2 , and the number of positive cells/mm 2 of cellular area was calculated. As macrophages were abundant within these tumours, the percent area of CD204+ staining (%CD204+) within each cellular area was determined using Image J, as previously described. 51 Briefly, the cellular area was measured ( Figure S1A , Supporting Information). Then, images were converted to a three-slice (red, green, blue) stack and "thresholded" to highlight only IHC positive cells ( Figure S1B ). Outlines of particles on the "thresholded" image were then overlain on the original image to ensure accurate coverage of positively labelled cells ( Figure S1C ). The area of these particles was then measured and the particle area was divided by the total cellular area in that image and multiplied by 100 to create the %CD204+ 
| Endpoints and statistical analysis
Disease-free interval (DFI) was defined as time from amputation to The Kaplan-Meier method was used to estimate median DFI and ST (MST), as well as the 2-year disease-free and survival rates. The logrank test was used to compare DFI and ST between groups. Any relationships between continuous variables (such as immune cell infiltrates and age) were evaluated using Spearman's correlation coefficient, and associations between categorical variables and immune infiltrates were determined using a Mann-Whitney test. Statistical analyses were performed using commercial software (GraphPad Prism version 7.0a, San
Diego, CA) and two-sided P values <0.05 were considered significant.
3 | RESULTS
| Clinical characteristics
Thirty dogs were enrolled between January 2010 and January 2014.
The mean age at amputation was 9.1 years (median = (Table 1) . 
| Quantification of infiltrating immune cells

| Association of immune cell infiltrates with clinical characteristics
The association of immune cell infiltrates with outcome was then evaluated (Table 2) . Dogs were initially differentiated as having "high"
or "low" infiltrate levels, by the median of each infiltrate. Only high % CD204+ infiltration was associated with improved DFI (P = 0.016; Figure 4A ). However, high %CD204+ infiltration was not prognostic for ST (P = 0.202; Figure 4B ). There was a numerical, but statistically insignificant, increase in median DFI and MST for dogs with high CD3 + (P = 0.484, P = 0.937; Figure S2A ,B), and high FOXP3+ (P = 0.224, P = 0.287; Figure S2C ,D) infiltration, and for dogs with a high FOXP3/ CD3% (P = 0.246, P = 0.276; Figure S2E ,F).
Next, we evaluated whether the dogs with the highest amount of inflammatory infiltrates experienced a different outcome to the remaining dogs (Table 3) . Here, dogs were defined as having "high"
infiltration if the quantity of inflammatory infiltrates was within the top quartile or "low" infiltration if they fell within the bottom 3 quartiles. Once again, high CD204+ infiltration was associated with improved DFI (P = 0.043; Figure S3A ), while this parameter did not have a significant effect on ST as an endpoint (P = 0.201; Figure S3B ). Finally, we determined if any clinical or pathologic factors could be associated with immune cell infiltration. A summary of these findings is displayed in Table 4 . Interestingly, we observed a significant decrease in CD204+ infiltrates in tumours located in the proximal humerus, compared to all other locations (P = 0.016; Figure 5A ). A trend toward decreased CD3+ and FOXP3+ infiltrates, and FOXP3/ CD3%, in proximal humeral lesions was also detected (P = 0.067, The outcomes of the 30 dogs with cOSA treated with amputation and six doses of adjuvant carboplatin chemotherapy reported herein are within the ranges reported previously for amputation and adjuvant carboplatin chemotherapy, indicating that this cohort is likely a fair representation of cOSA patients. In fact, outcomes are quite similar to those from a previous prospective study in which 25 dogs received six doses of adjuvant carboplatin. 16 The median DFI in that study was 425 days compared to 392 days here and the MST was 479 days compared to 455 days here. These results compare favourably with previously published retrospective studies reporting outcome in dogs prescribed 4 or 6 doses of adjuvant carboplatin. 2, 8 One retrospective study found a significantly lower risk of metastasis and death in dogs prescribed six doses of carboplatin in univariate analysis compared to other chemotherapy protocols, but that study did not identify significant differences in outcome in multivariate analysis. Abbreviations: DFI = disease-free interval; MST = median overall survival time. Abbreviations: ALP, alkaline phosphatase; hpf , high power field.
Tumour-infiltrating macrophages, however, are often described as becoming skewed toward the more "tumour-promoting" M2 (alternative) phenotype due to exposure to T helper type 2 (Th2) cytokines such as IL-4 and IL-13, and the immunosuppressive cytokines IL-10 and transforming growth factor-β. 55, 56 In contrast, macrophages stimulated by microbial products such as lipopolysaccharide, with or without concurrent exposure to proinflammatory cytokines such as tumour necrosis factor α and interferon γ can become "antitumour" M1 (classical) phenotype macrophages. 55, 56 However, this paradigm does not allow for the broad array of functional and phenotypic characteristics of macrophages particular to certain tumour types. 56, 57 Notwithstanding the diversity within macrophage subsets, reports on several human cancer types as well as canine mammary carcinomas, show macrophage infiltration as correlating with a worse prognosis. [57] [58] [59] [60] In contrast, however, most studies in hOSA have reported tumour infiltrating macrophages as being associated with improved outcomes, [27] [28] [29] although some conflicting data exist. 43 Furthermore, most studies in hOSA have shown total (CD14 + 27 or CD68+ 28, 29 ) macrophage infiltrates, or even M2 phenotypes (CD163+
29
) to positively correlate with outcome, indicating that differential macrophage polarization is likely not the cause of this prognostic finding in hOSA. Indeed, we identified macrophages using CD204 in our study due its well-documented cross-reactivity with canine tissue, but this marker is also commonly associated with M2-type macrophages. 61, 62 Supporting the notion of macrophages Despite the prognostic significance of proximal appendicular locations in humans, 68 potential correlations of immune infiltrates with the primary tumour site are rarely reported in hOSA. 28, 29, 43, 50, 69 Buddingh et al, however, observed CD14+ infiltrates to be an independent positive prognostic factor when humeral location was included in the model, suggesting tumour site and monocyte/macrophage infiltration were not associated in this study. 27 In fact, to the best of the authors' knowledge, no study has shown consistent differences in immune infiltrates between tumours located in different bones, although growing evidence suggests the tissue-dependent recruitment of ous immune subsets in other tumour types. [35] [36] [37] [38] Several studies in both dogs and humans have, however reported the presence of FOXP3+ cells within tumours to be a negative prognostic factor owing to the fact that these cells are generally thought to have regulatory T cell (Treg) activity. [86] [87] [88] [89] [90] More recently, however, human studies have observed FOXP3 to be expressed by some nonlymphoid normal and cancerous cells, in addition to being transiently expressed by nonregulatory T cells during their activation. [91] [92] [93] Indeed, this likely explains the variability of FOXP3-expressing cells as being associated with a poor, neutral or good prognosis in human cancers. 90 The broad functionality of FOXP3+ cells within tumours has unsurprisingly led to their prognostic significance being determined by their identification using multiple lymphoid markers, as well as the tumour type being studied. 90 In summary, our finding of high FOXP3/CD3% being asso- Despite this, it is possible that data loss due to incomplete follow-up may have influenced study results.
In conclusion, these results suggest that dogs with appendicular osteosarcoma prescribed six doses of carboplatin chemotherapy may have a modest DFI and ST benefit when compared to previously published data from dogs prescribed other chemotherapy protocols.
These findings may be due, in part, to a higher chemotherapy completion rate than has previously been reported with this chemotherapy protocol. Within this cohort of dogs, we identified CD204+ infiltration above the median to be associated with an improved DFI and appendicular tumour locations other than the proximal humerus. Further studies are needed to evaluate the possibility that poor macrophage recruitment is a contributing factor to the rapid progression of cOSA arising from the proximal humerus. Taken together, these data support macrophage recruitment and activation as immunotherapeutic strategies for treating cOSA.
